A novel cancer therapy: hTERT - CRISPR/Cas9

A novel cancer therapy: hTERT – CRISPR/Cas9

I propose halting telomerase production in cancer cells via CRISPRCas9. Telomerase preserves telomeres preventing cancer cells from reaching the Hayflick limit and succumbing to apoptosis. A functional telomerase inhibitor would be a viable way to combat cancer. Should telomerase production cease, the Hayflick limit would be reached within a few rounds of mitosis. I propose eradicating a vital telomerase component, hTERT, via CRISPRCas9. Cas9 and sgRNA will be administered in a lipid nanoparticle. The process set forth by myself is theoretically viable and apt for mass production. I have laid out a research plan, which, if followed, could prove the viability of my solution in vitro. Existing scientific knowledge suggests that my proposition is theoretically valid both in vitro and in vivo.